US5185147A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
Assignee: Cellular Products Inc
•
Filing: 1988-08-19
•
Granted: 1993-02-09
•
Expires: 2008-08-19
Abstract
Abstract Polypeptides in the size range 6-11 amino acids from discrete regions of the human immunodeficiency virus p17 protein are immunogenic and form the basis for diagnosis and therapy of HIV-related disease.
Inventors
- 👤 Lawrence D. Papsidero
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 07:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; C12; C12N; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16211; C12N2740/16222; Y; Y10; Y10S; Y10S530/00; Y10S530/82; Y10S530/826; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/221
Claims Analysis
Total Claims: 55
Claim 1
Independent Claim
95 words
A protein that consists of at least one polypeptide selected from the group consisting of Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:1, Glu-Leu-Asp-Arg-Trp-Glu, defined in the sequence listing as SEQ ID NO:2, Leu-Asp-Arg-Trp-Glu-Lys, defined in the sequence listing as SEQ ID NO:3, Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:4, Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:5, and Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:6, provided that said protein is not one found in a naturally occurring human immunodeficiency virus or other animal virus.
Claim 2
Dependent Claim
95 words
A protein that consists of at least one polypeptide selected from the group consisting of Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:1, Glu-Leu-Asp-Arg-Trp-Glu, defined in the sequence listing as SEQ ID NO:2, Leu-Asp-Arg-Trp-Glu-Lys, defined in the sequence listing as SEQ ID NO:3, Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:4, Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:5, and Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:6, provided that said protein is not one found in a naturally occurring human immunodeficiency virus or other animal virus.
Claim 3
Dependent Claim
116 words
A protein that consists of at least one polypeptide selected from the group consisting of Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:1, Glu-Leu-Asp-Arg-Trp-Glu, defined in the sequence listing as SEQ ID NO:2, Leu-Asp-Arg-Trp-Glu-Lys, defined in the sequence listing as SEQ ID NO:3, Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:4, Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:5, and Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:6, as an immunogen in order to produce either antibodies with reactivity against a portion of human immunodeficiency virus (HIV) or cells capable of producing said antibodies provided said protein is not part of naturally occurring HIV or other animal virus.
Claim 4
Dependent Claim
116 words
A protein that consists of at least one polypeptide selected from the group consisting of Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:1, Glu-Leu-Asp-Arg-Trp-Glu, defined in the sequence listing as SEQ ID NO:2, Leu-Asp-Arg-Trp-Glu-Lys, defined in the sequence listing as SEQ ID NO:3, Asp-Arg-Trp-Glu-Lys-Ile, defined in the sequence listing as SEQ ID NO:4, Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:5, and Glu-Leu-Asp-Arg-Trp-Glu-Lys-Ile-Arg-Leu-Arg, defined in the sequence listing as SEQ ID NO:6, as an immunogen in order to produce either antibodies with reactivity against a portion of human immunodeficiency virus (HIV) or cells capable of producing said antibodies provided said protein is not part of naturally occurring HIV or other animal virus.
Claim 5
Dependent Claim
11 words
An immunization inoculum consisting essentially of a protein of claim 1.
Claim 6
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 1.
Claim 7
Dependent Claim
24 words
A protein of claim 1, the selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:5.
Claim 8
Dependent Claim
24 words
A protein of claim 1, the selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:1.
Claim 9
Dependent Claim
66 words
A protein of claim 5 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:5.
Claim 10
Dependent Claim
66 words
A protein of claim 6 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:1.
Claim 11
Dependent Claim
84 words
A protein of claim 1, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:2 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:2.
Claim 12
Dependent Claim
85 words
A protein of claim 1, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:3 provided provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:3.
Claim 13
Dependent Claim
84 words
A protein of claim 1, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:4 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:4.
Claim 14
Dependent Claim
84 words
A protein of claim 1, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:6 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:6.
Claim 15
Dependent Claim
83 words
A process of inducing an immune system response which comprises the step of administering to a nonhuman mammal a protein that consist of at least one polypeptide selected from the group consisting of those with amino acid sequences defined in the Sequence Listing by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, provided that said protein is not one found in a naturally occurring human immunodeficiency virus or other animal virus.
Claim 16
Dependent Claim
83 words
A process of inducing an immune system response which comprises the step of administering to a nonhuman mammal a protein that consist of at least one polypeptide selected from the group consisting of those with amino acid sequences defined in the Sequence Listing by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, provided that said protein is not one found in a naturally occurring human immunodeficiency virus or other animal virus.
Claim 17
Dependent Claim
24 words
A process of claim 13, the selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:5.
Claim 18
Dependent Claim
24 words
A process of claim 13, the selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:1.
Claim 19
Dependent Claim
66 words
A process of claim 13 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:5.
Claim 20
Dependent Claim
66 words
A process of claim 15 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:1.
Claim 21
Dependent Claim
84 words
A process of claim 13, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:2 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:2.
Claim 22
Dependent Claim
84 words
A process of claim 13, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:3 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:3.
Claim 23
Dependent Claim
84 words
A process of claim 13, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:4 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:4.
Claim 24
Dependent Claim
84 words
A process of claim 13, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:6 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:6.
Claim 25
Dependent Claim
42 words
A process of claim 13 which further comprises the step of producing from the nonhuman mammal, either or both of the following: (1) antibodies that react with said selected polypeptide or (2) cells capable of producing antibodies that react with said polypeptide.
Claim 26
Dependent Claim
23 words
A process of claim 22, the selected polypeptide being one with the amino sequence defined in the Sequence Listing by SEQ ID NO:5.
Claim 27
Dependent Claim
24 words
A process of claim 22, the selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:1.
Claim 28
Dependent Claim
66 words
A process of claim 23 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:5.
Claim 29
Dependent Claim
66 words
A process of claim 24 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:1.
Claim 30
Dependent Claim
84 words
A process of claim 22, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:2 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:2.
Claim 31
Dependent Claim
84 words
A process of claim 22, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:3 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:3.
Claim 32
Dependent Claim
84 words
A process of claim 22, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:4 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:4.
Claim 33
Dependent Claim
84 words
A process of claim 22, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:6 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:6.
Claim 34
Dependent Claim
80 words
The process of claim 13 in which the protein is administered to a nonhuman mammal and, subsequent to the time the protein is administered, the antibodies of said nonhuman mammal subjected to an immunological assay which will reveal the presence of antibodies against the polypeptide selected from the group consisting of those with amino acids defined in the Sequence Listing by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
Claim 35
Dependent Claim
25 words
The process of claim 31, the selected polypeptide being one with the amino PG,59 acid sequence defined in the Sequence Listing by SEQ ID NO:5.
Claim 36
Dependent Claim
24 words
A process of claim 31, the selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:1.
Claim 37
Dependent Claim
66 words
A process of claim 32 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:5.
Claim 38
Dependent Claim
66 words
A process of claim 33 further provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:1.
Claim 39
Dependent Claim
84 words
A process of claim 31, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:2 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:2.
Claim 40
Dependent Claim
84 words
A process of claim 31, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:3 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:3.
Claim 41
Dependent Claim
84 words
A process of claim 31, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:4 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:4.
Claim 42
Dependent Claim
84 words
A process of claim 31, said selected polypeptide being one with the amino acid sequence defined in the Sequence Listing by SEQ ID NO:6 provided that, in said protein, a polypeptide linked by a peptide bond to either end of said selected polypeptide does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of a polypeptide with the amino sequence defined in the Sequence listing by SEQ ID NO:6.
Claim 43
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 5.
Claim 44
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 6.
Claim 45
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 7.
Claim 46
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 8.
Claim 47
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 9.
Claim 48
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 10.
Claim 49
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 11.
Claim 50
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 12.
Claim 51
Dependent Claim
60 words
A protein of claim 1 provided further that, in said protein, a polypeptide linked by a peptide bond to either end of a polypeptide selected from the group does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of the polypeptide selected from the group.
Claim 52
Dependent Claim
60 words
A protein of claim 13 provided further that, in said protein, a polypeptide linked by a peptide bond to either end of a polypeptide selected from the group does not have the same amino acid sequence as a polypeptide that, in naturally occurring human immunodeficiency virus p17 protein, is linked to an end of the polypeptide selected from the group.
Claim 53
Dependent Claim
44 words
The process of claim 49 which further comprises the step of isolating antibodies from the serum of the nonhuman mammal, either or both of the following: antibodies that react with said selected polypeptide or cells capable of producing antibodies that react with said polypeptide.
Claim 54
Dependent Claim
40 words
The process of claim 50 in which the protein is administered to a nonhuman mammal and which further comprises the step of subjecting the antibodies to an immunological assay which will reveal the presence of antibodies against the polypeptide selected.
Claim 55
Dependent Claim
10 words
A substantially pure preparation of a protein of claim 48.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-02-09 | 1996-08-10 | 1997-02-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-02-09 | 2000-08-10 | 2001-02-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-02-09 | 2004-08-10 | 2005-02-09 | $7700.00 | Window Closed / Lapsed |